

Hypoglycemia in the New Diabetes Era

BRITTANY SIEMIAWSKI DNP, APNP, PNP-PC
PEDIATRIC ENDOCRINOLOGY & DIABETES

Disclosures

- No financial disclosures

Objectives

- Define hypoglycemia, symptoms, and treatment
- Define physiological responses to hypoglycemia
- Analyze insulin pump systems and their proactive features to prevent hypoglycemia
- Summarize hypoglycemia treatment options for children on insulin pump therapy

Background

- Hypoglycemia is a large factor in diabetes management
 - Frightening for patients/families
 - Difficult to recognize/communicate needs (hypoglycemia unawareness)
 - Can lead to serious life-threatening consequences
- Young children with type 1 diabetes mellitus (T1D) are more vulnerable for clinically significant hypoglycemia because of their reduced ability to recognize symptoms and effectively communicate needs

Hypoglycemia in Diabetes


Broadly defined as a blood glucose level ≤ 70 mg/dL

Level	Glycemic criteria	
Hypoglycemia alert value (level 1)	≤ 70 mg/dl (3.9 mmol/L)	Sufficiently low for treatment with fast acting carbohydrate and dose adjustment of glucose lowering therapy
Clinically significant hypoglycemia (level 2)	< 54 mg/dl (3.0 mmol/L)	Sufficiently low to indicate serious, clinically important hypoglycemia
Severe hypoglycemia (level 3)	No specific glucose threshold	Hypoglycemia associated with severe cognitive impairment requiring external assistance for recovery

Physiological Defenses

- Physiological/counterregulatory responses to hypoglycemia:
 1. Insulin levels decrease
 2. Glucagon levels increase
 3. Epinephrine increases
- In T1D, beta cell deterioration/failure occurs ultimately leading to blunted physiological responses to hypoglycemia

Hypoglycemia-Associated Autonomic Failure



Symptoms of Hypoglycemia

- Sweating
- Irritability, nervousness
- Feeling shaky
- Confusion
- Hunger
- Nausea
- Lightheaded, dizziness
- Fatigue
- Feeling weak
- Seizure

Hypoglycemia Causes in T1D

- Insulin
 - Doses (high)
 - Wrong insulin (long-acting vs. rapid-acting)
 - Administration (accidentally injected in muscle vs. subcutaneous)
- Food
 - Eating less carbohydrates than dosed for
 - Absorption (fat, protein, fiber)
 - Timing of injection in relation to meal
- Physical activity
 - Physical education, recess

Treatment of Hypoglycemia

- “15-15 rule”
 - Treat with 15 fast-acting grams of carbohydrates and recheck blood glucose level in 15 minutes—if blood glucose level is still <70 mg/dL, treat again.
 - Examples: glucose tablets, 4 ounces of juice, skittles, fruit snacks
 - Glucagon for severe hypoglycemia
- *Physical Activity Considerations (gym class, recess)*
 - Eat an uncovered 15 grams carbs snack prior to activity
 - If eating/dosing within 2-3 hours of activity, can decrease insulin dose proactively

Insulin Pump Therapy

What is an insulin pump?

- Device that delivers insulin in two ways:
 - 1. Steady, background continuous dose (“basal”)
 - 2. Surges at mealtimes or instances of high blood glucose levels (“bolus”)
 - *No long-acting insulin, all rapid-acting insulin*
- Device details:
 - Insulin is delivered continuously through a flexible catheter underneath the skin
 - The pump is replaced every ~3 days
 - Various types on the market (i.e. Omnipod, Tandem, Medtronic)
 - Settings can be programmed on an hourly basis (carb ratios, correction factors, basal rates)

Insulin Pump Therapy Continued

Majority of insulin pumps are integrated with a continuous glucose monitor (CGM)


- CGM data is transmitted to the insulin pump → the pump automatically adjusts the insulin being delivered based off its algorithm/CGM reading
 - Hybrid closed-loop systems



(Tandem Diabetes Care, 2024)



(Medtronic, 2024)



(Insulet Omnipod 5, 2024)

Closed-Loop Insulin Pump Features

- Each pump has an individual algorithm with specific features

Generally:


- If an insulin pump senses the blood glucose/CGM reading is *dropping*, it will *decrease or suspend* the basal insulin rate
- If the insulin pump senses the blood glucose/CGM reading is *increasing*, it will *increase* the basal insulin rate or give an automatic correction dose
- Activity/exercise mode
- Sleep mode

Hypoglycemia Treatment on Insulin Pump Therapy

- If an insulin pump senses the blood glucose/CGM reading is dropping, it will decrease or suspend the basal insulin rate
 - *This means treatment for hypoglycemia may require less fast-acting carbs (<15 grams) to return to euglycemia*
 - *This avoids overtreatment on AID systems, which may subsequently result in hyperglycemia*
- Activity/exercise mode
 - *Targets a higher blood glucose, algorithm less aggressive*
 - *Must be turned on at least 1 hour before activity to reduce insulin on board going into activity*
- Additional proactive considerations:
 - *Reduce mealtime bolus before activity*
 - *Pre-meal dosing*


Examples

Omnipod 5



Examples

Tandem T-slim



Summary

- Hypoglycemia is a limiting factor in T1D management
- Physiological responses to hypoglycemia are blunted in T1D
- Hypoglycemia is generally defined as a blood glucose level <70 mg/dL
- Symptoms of hypoglycemia include irritability, sweating, hunger, weakness
- Technology is helpful in reducing hypoglycemia (CGMs, insulin pumps)
- Treatment for hypoglycemia on insulin pump therapy may include
 - Activity mode proactively
 - Less fast-acting carbs (<15 grams)
- Other features to consider to prevent hypoglycemia on insulin pump therapy:
 - Pre-meal dosing
 - Reduce bolus dose proactively before activity

Thank you!



References

- American Diabetes Association. (2018). Glycemic Targets: Standards of Medical Care in Diabetes-2018. *Diabetes Care*, 41(1), S55-S64. <https://doi.org/10.2337/dc18-S006>
- American Diabetes Association. (2023). *Treatment & care: Hypoglycemia (Low blood glucose)*. <https://diabetes.org/living-with-diabetes/treatment-care/hypoglycemia>
- American Diabetes Association. (2023). *About diabetes: Insulin pumps: Relief and choice*. <https://diabetes.org/about-diabetes/devices-technology/insulin-pumps-relief-and-choice>
- Davis, H. A., Spanakis, E. K., Cryer, P. E., & Davis, S. N. (2021). Hypoglycemia during therapy of diabetes. *Endotext*. <https://www.ncbi.nlm.nih.gov/books/NBK279100/#>
- Sherr, J. L, Heinemann, L., Fleming, A., Bergenstal, R. M., Bruttomesso, D., Hanaire, H., Holl, R. W., Petrie, J. R., Peters, A. L., & Evans, M. (2022). Automated insulin delivery: Benefits, challenges, and recommendations. A consensus report of the joint diabetes technology working group of the European Association for the study of diabetes and the American Diabetes Association. *Diabetes Care*, 45(12), 3058-3074. <https://doi.org/10.2337/dci22-0018>